IMPORTANCE Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.OBJECTIVE To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS.DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, observational, retrospective, comparative effectiveness research study. Data were extracted on November 28, 2018, from the Italian multiple sclerosis register and analyzed from June to December 2021. Mean study follow-up was 11 years. Included in the study cohort were patients with a diagnosis of PPMS and at least 3 years of Expanded Disability Status Scale (EDSS) evaluations and 3 years of follow-up.MAIN OUTCOMES AND MEASURES The risk of reaching an EDSS score of 7.0 was assessed through multivariable Cox regression models.EXPOSURES Patients who received DMT before the outcome were considered treated. DMT was assessed as a time-dependent variable and by class of DMT (moderately and highly effective).RESULTS From a total of 3298 patients with PPMS, 2633 were excluded because they did not meet the entry criteria for the phase 3, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with PPMS (ORATORIO) trial. Among the remaining 665 patients (mean [SD] age, 43.0 [10.7] years; 366 female patients [55.0%]), 409 were further selected for propensity score matching (288 treated and 121 untreated patients). In the matched cohort, during the study follow-up, 37% of patients (152 of 409) reached an EDSS score of 7.0 after a mean (SD) follow-up of 10.6 (5.6) years. A higher EDSS score at baseline (adjusted hazard ratio [aHR], 1.32; 95% CI, 1.13-1.55; P < .001), superimposed relapses (aHR, 2.37; 95% CI, 1.24-4.54; P = .009), and DMT exposure (aHR, 1.75; 95% CI, 1.04-2.94; P = .03) were associated with a higher risk of an EDSS score of 7.0, whereas the interaction term between DMT and superimposed relapses was associated with a reduced risk of EDSS score of 7.0 (aHR, 0.33; 95% CI, 0.16-0.71; P = .004). Similar findings were obtained when treatment according to DMT class was considered and when DMT was included as a time-dependent covariate. These results were confirmed in the subgroup of patients with available magnetic resonance imaging data.CONCLUSIONS AND RELEVANCE Results of this comparative effectiveness research study suggest that inflammation also occurs in patients with PPMS, may contribute to long-term disability, and may be associated with a reduced risk of becoming wheelchair dependent by current licensed DMTs.

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis / Portaccio, Emilio; Fonderico, Mattia; Iaffaldano, Pietro; Pastò, Luisa; Razzolini, Lorenzo; Bellinvia, Angelo; De Luca, Giovanna; Ragonese, Paolo; Patti, Francesco; Brescia Morra, Vincenzo; Cocco, Eleonora; Sola, Patrizia; Inglese, Matilde; Lus, Giacomo; Pozzilli, Carlo; Maimone, Davide; Lugaresi, Alessandra; Gazzola, Paola; Comi, Giancarlo; Pesci, Ilaria; Spitaleri, Daniele; Rezzonico, Marta; Vianello, Marika; Avolio, Carlo; Logullo, Francesco O; Granella, Franco; Salvetti, Marco; Zaffaroni, Mauro; Lucisano, Giuseppe; Filippi, Massimo; Trojano, Maria; Amato, Maria Pia. - In: JAMA NEUROLOGY. - ISSN 2168-6149. - 79:9(2022), pp. 869-878. [10.1001/jamaneurol.2022.1929]

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

Granella, Franco;
2022-01-01

Abstract

IMPORTANCE Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.OBJECTIVE To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS.DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, observational, retrospective, comparative effectiveness research study. Data were extracted on November 28, 2018, from the Italian multiple sclerosis register and analyzed from June to December 2021. Mean study follow-up was 11 years. Included in the study cohort were patients with a diagnosis of PPMS and at least 3 years of Expanded Disability Status Scale (EDSS) evaluations and 3 years of follow-up.MAIN OUTCOMES AND MEASURES The risk of reaching an EDSS score of 7.0 was assessed through multivariable Cox regression models.EXPOSURES Patients who received DMT before the outcome were considered treated. DMT was assessed as a time-dependent variable and by class of DMT (moderately and highly effective).RESULTS From a total of 3298 patients with PPMS, 2633 were excluded because they did not meet the entry criteria for the phase 3, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with PPMS (ORATORIO) trial. Among the remaining 665 patients (mean [SD] age, 43.0 [10.7] years; 366 female patients [55.0%]), 409 were further selected for propensity score matching (288 treated and 121 untreated patients). In the matched cohort, during the study follow-up, 37% of patients (152 of 409) reached an EDSS score of 7.0 after a mean (SD) follow-up of 10.6 (5.6) years. A higher EDSS score at baseline (adjusted hazard ratio [aHR], 1.32; 95% CI, 1.13-1.55; P < .001), superimposed relapses (aHR, 2.37; 95% CI, 1.24-4.54; P = .009), and DMT exposure (aHR, 1.75; 95% CI, 1.04-2.94; P = .03) were associated with a higher risk of an EDSS score of 7.0, whereas the interaction term between DMT and superimposed relapses was associated with a reduced risk of EDSS score of 7.0 (aHR, 0.33; 95% CI, 0.16-0.71; P = .004). Similar findings were obtained when treatment according to DMT class was considered and when DMT was included as a time-dependent covariate. These results were confirmed in the subgroup of patients with available magnetic resonance imaging data.CONCLUSIONS AND RELEVANCE Results of this comparative effectiveness research study suggest that inflammation also occurs in patients with PPMS, may contribute to long-term disability, and may be associated with a reduced risk of becoming wheelchair dependent by current licensed DMTs.
2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis / Portaccio, Emilio; Fonderico, Mattia; Iaffaldano, Pietro; Pastò, Luisa; Razzolini, Lorenzo; Bellinvia, Angelo; De Luca, Giovanna; Ragonese, Paolo; Patti, Francesco; Brescia Morra, Vincenzo; Cocco, Eleonora; Sola, Patrizia; Inglese, Matilde; Lus, Giacomo; Pozzilli, Carlo; Maimone, Davide; Lugaresi, Alessandra; Gazzola, Paola; Comi, Giancarlo; Pesci, Ilaria; Spitaleri, Daniele; Rezzonico, Marta; Vianello, Marika; Avolio, Carlo; Logullo, Francesco O; Granella, Franco; Salvetti, Marco; Zaffaroni, Mauro; Lucisano, Giuseppe; Filippi, Massimo; Trojano, Maria; Amato, Maria Pia. - In: JAMA NEUROLOGY. - ISSN 2168-6149. - 79:9(2022), pp. 869-878. [10.1001/jamaneurol.2022.1929]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2936760
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact